Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lorus Therapeutics LORFF LOR -- Ignore unavailable to you. Want to Upgrade?

To: Rampant who wrote (54)	2/19/2000 12:18:00 AM
From: dennis naughler	Read Replies (3) \| Respond to of 101

Speculation & then reality Believe me man!!!I got burned badly in the past on similar biotech plays. Anybody who is betting on a positive preclinical results from Lorus will be very disappointed. This worthless writeup from The Global&Mail is there for one reason to keep everyone speculating for a positive result announcement while big boys quietly unloading their shares. The Globe and Mail reports in its Tuesday, Feb. 8, edition that Lorus Therapeutics gained 29 cents to $2.57 yesterday on the Toronto Stock Exchange. The Globe's Market Movers column reports that the Montreal-based company's NuChem Pharmaceuticals unit has determined that its key anticancer drug NC 381 has shown positive preclinical results in tests using mice with human tumour cells. More than 3.8 million shares changed hands yesterday, says The Globe.